Also for enzyme replacement therapy (ERT), there was no significant effect on VEGF and angiostatin concentrations, although there was a trend toward lower VEGF concentrations in patients with Fabry’s disease under ERT compared with those in therapy-naive patients with Fabry’s disease (data not provided). This evidence concerns the gene VEGFA and Fabry disease.